Key Takeaways

  • Detox alone is not treatment; previous attempts often stalled because comprehensive support between withdrawal and the first six months post-discharge was missing 7, 15.
  • A thorough clinical assessment covering medical, psychiatric, and practical factors should drive the treatment plan, because untreated co-occurring conditions frequently explain repeated relapse.
  • Medically supervised withdrawal manages acute physical symptoms safely but must include MOUD consideration and a same-day handoff to ongoing care 15, 20.
  • NIDA identifies roughly three months as the minimum treatment duration for meaningful change, achievable through residential care combined with step-down levels 16.
  • Residential programming works best when medication decisions happen in week one and days are filled with behavioral therapy, contingency management, and structured peer contact 18, 20.
  • Post-discharge relapse estimates range from 0% to 95%, with the quality of the discharge plan—not the inpatient stay alone—driving which end you land on 3.
  • A concrete discharge plan with confirmed housing, scheduled peer support, filled prescriptions, and coached digital tools alongside clinical care measurably reduces relapse risk 1, 2, 4.
  • Reduced tolerance after residential care makes overdose risk acute, so naloxone, continued OUD medication, and a 72-hour contact plan should leave with you 3, 10.

Why Your Last Attempt Stalled After Detox

You’ve been through detox before, perhaps multiple times. You completed the initial withdrawal phase, felt a shift, but then weeks later, something broke, and you found yourself back where you started. This experience can be compounded by increased shame and a lowered tolerance, which heightens risk.

If your previous attempts involved only detox followed by minimal support, the issue was likely structural, not a personal failing. Research from the National Institute on Drug Abuse (NIDA) suggests that a minimum of three months in treatment is generally required to significantly reduce or stop substance use, with longer durations often leading to better outcomes 16. Short stays and detox-only approaches fall short of this recommended duration.

The goal for this attempt isn’t just to get clean again, as you’ve proven you can do that. The critical question is what comprehensive support and strategies are implemented between the end of withdrawal and the first six months post-discharge, as this period is often where previous attempts faltered.

Step One Is an Assessment, Not an Admission

While admission to many residential programs can be straightforward, the true first step is a thorough clinical assessment. This involves a structured conversation and evaluations designed to answer three key questions before determining the appropriate course of treatment for the next 30, 60, or 90 days.

The assessment addresses three domains:

  1. Medical needs: what substances are being used, in what quantities and frequency, and what physiological responses are expected during withdrawal? Alcohol and benzodiazepine withdrawal can be medically dangerous without supervision, while opioid withdrawal, though rarely fatal, is intensely uncomfortable and often leads to early departure from treatment.
  2. Psychiatric co-occurring conditions: what other mental health issues are present? Conditions like depression, anxiety, PTSD, bipolar disorder, ADHD, unresolved grief, or past traumatic brain injuries are not secondary concerns. For individuals experiencing chronic relapse, an untreated co-occurring condition is frequently the underlying reason previous plans failed after an initial period of success.
  3. Practical considerations: where will you live post-discharge, who is in your support network, what is your employment situation, and what specific components were included in previous treatment attempts?

Trauma assessment should be an integral part of the first week of treatment, not delayed until later. A 2024 study on a trauma-informed residential model for substance use treatment reported an 88% fidelity in delivery, with 48% of clients completing the six-week program. Participants showed improvements in substance use, depression, anxiety, and PTSD at three months 13. This completion rate highlights that even well-executed trauma-informed programs lose a significant portion of clients. A comprehensive assessment allows clinicians to identify individuals at risk of leaving early and adjust the treatment plan to improve retention.

If an intake call feels like a sales pitch, consider it a warning sign. A serious clinical assessment requires several hours, involves both medical and behavioral-health professionals, and culminates in a written treatment plan. This plan should clearly outline your specific risks, prescribed medications, therapy track, and the framework of your discharge plan. You have a right to review this document; if it’s not provided, request it.

Medically Supervised Withdrawal: What It Is and What It Isn’t

Withdrawal is a medical event, often mistakenly equated with the entirety of the recovery process. This misunderstanding can contribute to repeated treatment attempts.

Medically supervised withdrawal safely manages the acute physical phase of detoxification. For alcohol, this involves monitoring and often administering benzodiazepines on a tapered schedule to manage risks such as seizures, delirium tremens, and dangerous blood-pressure fluctuations. For benzodiazepine withdrawal, a slow, structured taper is essential to prevent severe complications. For opioids, medical supervision focuses on managing intensely uncomfortable but rarely life-threatening symptoms. Crucially, it also involves initiating medication for opioid use disorder (MOUD) when appropriate, rather than treating withdrawal as the final step.

The failure to initiate MOUD during or after opioid withdrawal is a common reason previous attempts have failed. The CDC states that detoxification without MOUD is not recommended, as the risks of resumed use, overdose, and overdose death increase after forced abstinence 15. SAMHSA’s TIP 63 further emphasizes that methadone, buprenorphine, and naltrexone significantly reduce illicit opioid use, improve treatment retention, and lower the risk of opioid-overdose death compared to placebo or no medication 20. If a program detoxes you from opioids but does not discuss MOUD, it is not adhering to modern standards of care.

It is important to reiterate that medically supervised withdrawal is not treatment. As the NIAAA states for alcohol, detoxification is a critical first step but not a complete treatment 7. During withdrawal, your tolerance resets, but cravings, sleep disturbances, emotional volatility, and environmental cues remain unaddressed. These aspects require months of ongoing management and therapeutic work.

When inquiring about a program’s detox services, ask two specific follow-up questions:

If the answer involves discharge with only a referral list, this represents a significant gap that could undermine recovery.

The Three-Month Floor and Why Short Stays Keep Failing You

If you’ve experienced repeated cycles of 28-day stays followed by relapse, the duration of treatment was likely insufficient from the outset. NIDA’s research-based guidelines indicate that approximately three months of treatment is a minimum threshold to significantly reduce or stop drug use, with longer durations generally yielding better outcomes 16. A four-week stay is not merely a shorter version of adequate treatment; it is fundamentally different, serving more as extended stabilization than a comprehensive process for sustained behavioral change.

Three months is a minimum, not a guarantee. The effectiveness of this period depends heavily on the activities within those weeks:

  1. The initial phase often focuses on physical recovery, sleep restoration, and medication adjustments.
  2. The middle phase is where behavioral therapy, trauma work, and deeper discussions about family dynamics and work-life integration become possible, as your nervous system stabilizes.
  3. The final phase, often omitted in short stays, is crucial for rehearsing and solidifying the discharge plan while clinical support is still readily available.

If a 90-day residential stay is not feasible, the alternative is not to forgo treatment, but to extend the structured phase through step-down levels of care. For example, a 30-day residential stay combined with intensive outpatient programs, sober housing, and continuing-care groups can approximate the duration recommended by NIDA. However, a 30-day stay followed by no structured aftercare is unlikely to be effective. Short stays often fail because they are not designed to provide the full scope of support needed for long-term recovery, a fact often not explicitly communicated.

Inside Structured Residential Programming

Medication Decisions Belong in the First Week

For individuals with opioid use disorder, discussions about medication should occur within the first week of treatment, not postponed until you’ve “proven” your commitment. SAMHSA’s TIP 63 identifies methadone, buprenorphine, and naltrexone as FDA-approved medications for OUD, noting their effectiveness in reducing illicit opioid use, improving treatment retention, and lowering the risk of opioid-overdose death compared to placebo or no medication 20. The CDC reinforces this, stating that evidence-based OUD treatment integrates medication with behavioral therapy, and detoxification without MOUD is not recommended 9, 15.

For alcohol use disorder, the approach is similar, though the medications differ. NIAAA recognizes naltrexone, acamprosate, and disulfiram as FDA-approved options, viewing them as complementary to behavioral therapy rather than a substitute 8. If previous treatment experiences led you to believe medication was a “crutch” or indicated a lack of effort, this perspective is inconsistent with current clinical evidence.

Practically, by the end of your first week, your treatment plan should explicitly document which medications were considered, which were chosen or declined, and the rationale behind these decisions. If you decline medication, the plan should outline alternative strategies and when the discussion will be revisited. Deferring medication decisions often means they are never made effectively, leading to missed opportunities for support.

Behavioral Therapy, Contingency Management, and Peer Contact

The majority of your daytime hours in residential treatment will be dedicated to therapy, and the variety of approaches is important. NIAAA supports various behavioral therapies, including cognitive-behavioral therapy, motivational interviewing, mindfulness-based interventions, contingency management, 12-step facilitation, and couples or family therapy 7. An effective program integrates these approaches, recognizing that different stages of recovery require different therapeutic strategies.

Contingency management is a component often overlooked in previous treatment attempts. A 2024 meta-analysis of 84 studies involving approximately 11,000 participants reported a moderate post-treatment abstinence effect (d=0.54) compared to control groups, with a smaller follow-up effect (d=0.08) after incentives ceased. This evidence is strong enough to warrant a strong recommendation for contingency management as an empirically supported treatment for drug-use disorders 18. A 2025 review found moderate-to-large effects when targeting a single substance, with cocaine abstinence effects exceeding what incentive value alone would predict 11. This means that providing small, tangible rewards for verified abstinence or attendance is effective. The reduced effect after incentives end highlights the need to transition these gains into continuing care.

Peer contact is an essential complement to clinical work. A realist review of residential treatment identified belonging, meaning in life, and self-determination as key mechanisms of recovery, fostered by interactions with peers undergoing similar experiences 17. If your treatment schedule lacks opportunities for meaningful peer interaction, a crucial element of support may be missing.

The Post-Discharge Cliff: Where Relapse Risk Concentrates

This data strongly implies that the discharge plan is a primary determinant of long-term success, often more so than the inpatient stay itself. Two individuals leaving the same program on the same day can have vastly different outcomes. One might transition to sober housing, have a filled buprenorphine prescription, receive regular calls from a peer coach, and begin an intensive outpatient program within days. The other might be discharged to a motel with only a pamphlet. Their probabilities of relapse are not comparable, and no clinician should suggest otherwise.

The period from the first week to the first ninety days post-discharge is when relapse risk is highest. Your nervous system is still adjusting, and your tolerance has decreased, which is particularly dangerous if you have a history of opioid use. The structured therapeutic environment that occupied your days is suddenly absent, and familiar cues—places, people, specific times of day—re-emerge.

None of these factors make relapse inevitable. Instead, they underscore the importance of the discharge plan as the actual intervention. If you leave with vague instructions to “find a meeting” and a list of referrals, you are at the higher end of that 0-95% relapse range. If you leave with confirmed appointments, filled prescriptions, secured housing, and a designated contact person expecting your call, you are positioned at the lower end. This proactive planning is the most significant lever for sustained recovery.

Building the Discharge Plan Before You Leave the Bed

Housing, Peer Support, and Continuing Care

Your discharge plan should be a concrete document, available for review at least a week before you leave. It should include a schedule with addresses, phone numbers, dates, and the names of individuals who are expecting you. Three elements are particularly crucial:

  • Stable housing
  • Consistent peer support
  • A structured clinical framework to replace the residential setting

Housing is paramount, as other recovery efforts are often undermined without it. A 2025 systematic review of recovery housing—abstinence-based living environments combining stable shelter with recovery support—found that residents generally outperformed control groups in abstinence, income, employment, criminal charges, and cost-effectiveness over six to 24 months 1. While the evidence is rated moderate, and policies on MOUD vary, it is essential to confirm that MOUD is permitted if it is part of your treatment plan 1.

Peer support forms the second layer of essential post-discharge care. A 2025 scoping review of recovery-support services linked peer-delivered interventions to lower relapse and readmission rates, increased engagement, and stronger social support 2. These are not informal favors; for example, one recovery community center served 721 individuals in a year with a budget of $876,831, allocating a significant portion to walk-in services, meetings, laundry, computers, and meals 12. Peer contact should be treated as scheduled infrastructure, not something to “look into” later.

Continuing care provides the clinical continuity. This includes scheduled outpatient appointments, filled prescriptions, and a therapist who has already reviewed your intake notes. All these elements should be arranged before you leave the residential facility.

Digital Supports: What Helps, What’s Oversold

The reality of digital tools in recovery is often less glamorous than marketing suggests. Some digital tools genuinely reduce relapse risk when integrated with clinical care, while others are promising but require more research, and some are significantly oversold.

Strong evidence comes from two recent studies. A 2025 randomized controlled trial found that a smartphone app combined with telephone coaching, used as transitional support after inpatient alcohol treatment, reduced six-month relapse risk by approximately 33% compared to standard continuing care (adjusted hazard ratio 0.67, 95% CI 0.48–0.92) 4. A 2025 meta-analysis of 17 interventions revealed that when remote or digital tools supplemented in-person care, relapse odds were 39% lower than with in-person care alone (odds ratio 0.61) 6. Both studies emphasize that these tools are effective when used alongside clinical care, not as a replacement. The same meta-analysis was less conclusive about digital tools that entirely replaced in-person treatment 6.

Wearables are often the most oversold technology. A 2025 integrative review of 58 studies on remote monitoring for alcohol use disorder found that smartphones and breathalyzers had greater immediate clinical applicability than passive wearable sensors, with adherence and psychological barriers remaining unresolved for wearables 5. An earlier systematic review of wearable monitoring for non-alcohol, non-nicotine substance use screened nearly 2,000 papers but included only 15, most of which focused on intoxication, used small samples, and had low monitoring compliance. The authors concluded that evidence was insufficient to support wearable monitoring for substance use disorders 19.

For your discharge plan, a coached app and scheduled phone contact are worth pursuing. However, a wrist device promising to predict or prevent relapse is not yet a reliable tool.

Infographic showing Reduction in relapse odds when remote interventions supplement in-person care
Reduction in relapse odds when remote interventions supplement in-person care
Infographic showing Reduction in 6-month relapse risk with smartphone intervention vs standard care
Reduction in 6-month relapse risk with smartphone intervention vs standard care

Overdose Risk After Residential Care

CDC guidance integrates naloxone, overdose education, and continued medication access as essential components of discharge planning, not optional additions. The agency recommends expanding naloxone access to at-risk individuals and their family members or close contacts, alongside sustained access to OUD treatment 10. Medication treatment itself is associated with a reduced risk of overdose and overall mortality 15.

Local context also plays a role. For instance, Arkansas provisional data recorded 372 drug-overdose deaths in 2025, a slight decrease from 389 in 2024, but still a significant and unsafe number 14.

Three crucial items should accompany you upon discharge:

  1. Naloxone, stored in a place known and accessible to your partner or roommate
  2. A filled prescription for any OUD medication included in your plan
  3. A written agreement detailing who you will contact within the first 72 hours

This is not a pessimistic view of your recovery attempt, but a practical and life-saving measure for day one.

If You Relapse Again, What Changes

It’s important to approach relapse with an honest perspective: NIDA characterizes addiction as a chronic condition, and recovery as a long-term process that may involve multiple treatment episodes 16. A return to substance use is a clinical event that provides valuable information about what was missing from the previous plan; it is not a judgment on you as a person.

If relapse occurs, specific changes are necessary immediately:

  • The medication question should be re-evaluated: if you were on buprenorphine or naltrexone and stopped, the reasons should be explored, and re-initiation considered. If these medications were never offered, that conversation must happen now 20.
  • Overdose risk must be reassessed as a priority, given the shift in tolerance; naloxone should be readily available, and your support network informed of its location 10.
  • Housing arrangements should also be re-examined to ensure they genuinely support your recovery plan.

Following these immediate adjustments, the more intensive work begins: returning to a structured phase of care. This phase should be long enough to meet NIDA’s three-month minimum, potentially through a combination of residential and step-down levels of care 16. Peer contact should be scheduled and consistent, not merely hoped for 2. If contingency management is available, it should be utilized 18.

Each attempt provides more information than the last. This accumulated knowledge is a valuable starting point for building a more effective recovery plan.

Chart showing Operating Costs of a Recovery Community Center (1 year)
A 2025 study reported the operating costs for a standard recovery community center program that enrolled 721 people over one year. A portion of the total cost supported community services like walk-ins, meetings, and meals.

Frequently Asked Questions

Is detox the same as treatment?

No. The NIAAA explicitly states that medically supervised withdrawal is a critical first step, but it is not comprehensive alcohol treatment by itself 7. Detox stabilizes your body through the acute withdrawal phase, while treatment addresses the underlying behavioral, psychiatric, and social patterns contributing to substance use. If a previous attempt involved only detox followed by a referral list, you received only the initial step, not a complete recovery plan.

How long does residential treatment need to be to actually work?

NIDA’s research-based guide suggests a minimum of approximately three months in treatment to significantly reduce or stop substance use, with longer durations generally leading to better outcomes 16. This duration can be achieved through a single extended residential stay or a shorter stay followed by intensive outpatient programs, sober housing, and continuing-care groups. A 28-day stay without structured aftercare falls short of evidence-supported recommendations.

Do I need medication if I’ve been through detox before?

For opioid use disorder, medication is almost certainly recommended. SAMHSA’s TIP 63 indicates that methadone, buprenorphine, and naltrexone reduce illicit opioid use, improve treatment retention, and lower the risk of overdose death compared to placebo or no medication 20. The CDC advises against detoxification without MOUD 15. For alcohol use disorder, naltrexone, acamprosate, and disulfiram are FDA-approved options that warrant a thorough discussion with your clinician 8.

Why is relapse risk so high right after discharge?

Several factors converge post-discharge: your tolerance to substances decreases, the structured therapeutic environment is removed, and old environmental cues reappear. A 2025 systematic review of non-hospital residential OUD treatment found post-discharge relapse estimates ranging from 0% to 95% across 10 studies. This wide range was largely influenced by whether individuals connected to continuing care, medication, and stable housing after leaving treatment 3. The discharge plan is therefore a critical factor in mitigating this risk.

Can an app or wearable replace in-person continuing care?

No, but digital tools can significantly enhance in-person care. A 2025 meta-analysis found that remote interventions, when added to in-person care, reduced relapse odds by 39% compared to in-person care alone, though evidence for digital tools replacing in-person treatment was less conclusive 6. Wearables remain under-studied; a systematic review of wearable monitoring for substance use concluded that current evidence is insufficient to support them as standalone tools 19. Technology should be used to supplement, not replace, clinical support.

If I relapse again, does that mean treatment failed?

No. NIDA describes addiction as a chronic condition and recovery as a long-term process that may require multiple treatment episodes 16. A return to substance use provides clinical information about what elements were missing from the previous plan, often related to medication, housing, or consistent continuing care. The appropriate next steps involve reassessment: re-evaluating medication options, ensuring naloxone and overdose planning are in place 10, and re-establishing a structured phase of care long enough to meet the three-month minimum.

References

  1. Recovery housing for substance use disorder: a systematic review. https://pubmed.ncbi.nlm.nih.gov/40115346/
  2. Recovery support services as part of the continuum of care for alcohol or drug use disorders. https://pubmed.ncbi.nlm.nih.gov/39873444/
  3. Risk of Relapse Following Discharge from Non-Hospital Residential Opioid Use Disorder Treatment: A Systematic Review of Studies Published from 2018 to 2022. https://pubmed.ncbi.nlm.nih.gov/40297541/
  4. Evaluation of a Smartphone App Intervention with Telephone Guidance as Transitional Support from Inpatient Treatment to Continuing Care for Individuals with Alcohol Use Disorder: Results from a Randomized Controlled Trial. https://pubmed.ncbi.nlm.nih.gov/40414214/
  5. Current approaches using remote monitoring technology in alcohol use disorder (AUD): an integrative review. https://pubmed.ncbi.nlm.nih.gov/40501058/
  6. How effective are remote and/or digital interventions as part of alcohol and drug treatment and recovery support? A systematic review and meta-analysis. https://pubmed.ncbi.nlm.nih.gov/40129216/
  7. Alcohol Use Disorder: From Risk to Diagnosis to Recovery. https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol/alcohol-use-disorder-risk-diagnosis-recovery
  8. Treatment for Alcohol Problems: Finding and Getting Help. https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/treatment-alcohol-problems-finding-and-getting-help
  9. Treatment of Opioid Use Disorder | Overdose Prevention. https://www.cdc.gov/overdose-prevention/treatment/opioid-use-disorder.html
  10. Preventing Opioid Overdose. https://www.cdc.gov/overdose-prevention/prevention/index.html
  11. Contingency management for monosubstance use disorders: Systematic review and assessment of predicted versus obtained effects. https://pubmed.ncbi.nlm.nih.gov/39545650/
  12. The costs of peer recovery support services provided through two recovery community centers. https://pubmed.ncbi.nlm.nih.gov/39993714/
  13. Feasibility and outcomes of a trauma-informed model of care in residential substance use treatment. https://pubmed.ncbi.nlm.nih.gov/39566845/
  14. Substance Misuse Education and Prevention – Arkansas Department of Health. https://healthy.arkansas.gov/programs-services/prevention-healthy-living/substance-misuse-education-and-prevention/
  15. Opioid Use Disorder: Treating | Overdose Prevention. https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html
  16. Principles of Drug Addiction Treatment: A Research-Based Guide. https://nida.nih.gov/sites/default/files/podat-3rdEd-508.pdf
  17. A realist review of residential treatment for adults with substance use disorder. https://pubmed.ncbi.nlm.nih.gov/36747370/
  18. Contingency Management for Drug Use Disorders: Meta-Analysis and Application of Tolin’s Criteria. https://pubmed.ncbi.nlm.nih.gov/38863566/
  19. Systematic review: Wearable remote monitoring to detect nonalcohol/nonnicotine-related substance use disorder symptoms. https://pubmed.ncbi.nlm.nih.gov/36062888/
  20. TIP 63: Medications for Opioid Use Disorder. https://library.samhsa.gov/sites/default/files/pep21-02-01-002.pdf
  21. Peer Recovery Support Services and Recovery Coaching for …. https://pubmed.ncbi.nlm.nih.gov/41551498/?fc=20220524061305&ff=20260907204034&v=2.20.1